Minerva Q2 GAAP net income $17.5M on $27.6M non-cash warrant gain; adjusted loss $7.8M

Minerva Neurosciences, Inc.

Q2 2026 GAAP net income of $17.5M ($0.36 basic, $(0.14) diluted) vs net loss of $3.3M year-ago; driven by $27.6M non-cash warrant gain.
Adjusted non-GAAP net loss of $7.8M vs $3.0M year-ago; H1 adjusted loss $15.1M vs $6.4M. Cash $75.4M, down from $82.4M at Dec 31, 2025.
R&D expense $7.2M (Q2) vs $1.3M; G&A $3.5M vs $2.1M, up on C19 trial costs, professional fees and compensation.
Phase 3 C19 roluperidone trial (380 patients, ~40 sites) on track; Phase A topline expected 2H 2027, Phase B 2H 2028.
Scientific Advisory Board expanded to 11 members, adding Correll, Leucht and Sand.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.